Results tagged “Vaccine Development” from Vaccination News

By MIKE STOBBE (AP) - Jul 17, 2009

ATLANTA -- The last time the government embarked on a major vaccine campaign against a new swine flu, thousands filed claims contending they suffered side effects from the shots. This time, the government has already taken steps to head that off.

Vaccine makers and federal officials will be immune from lawsuits that result from any new swine flu vaccine, under a document signed by Secretary of Health and Human Services Kathleen Sebelius, government health officials said Friday.

Since the 1980s, the government has protected vaccine makers against lawsuits over the use of childhood vaccines. Instead, a federal court handles claims and decides who will be paid from a special fund.

"If I had a child now, the last thing I would allow is vaccination."
-Retired Vaccine Researcher to Jon Rappoport
 
Editor's Note -- This interview was posted by Jon Rappoport in early January 2002. You will discover by reading it that the very issues we now face of FORCED vaccination of a laboratory-created vaccine to "protect" us against a laboratory-created "disease" (Swine Flu, Bird flu, etc.) was set into motion a long time ago.

The vaccine researcher quoted here flat out says that the World Homicide Organization, WHO, is driven by a DEPOPULATION agenda, and that many African leaders know full well that the explosive spread of HIV and AIDS in Africa was caused by WHO-sponsored vaccinations of the 1970s.

Canadian doctor Ghislaine Lanctôt, author of the Medical Mafia, has underscored the lawsuit recently filed by Austrian journalist Jane Bürgermeister against the WHO, the UN, and several high ranking government and corporate officials. Bürgermeister has documented how an international corporate criminal syndicate plans to unleash a deadly flu virus and institute a forced vaccination program.

"I am emerging from a long silence on the subject of vaccination, because I feel that, this time, the stakes involved are huge. The consequences may spread much further than anticipated," writes Lanctôt, who believes the A(H1N1) virus will be used in a pandemic concocted and orchestrated by the WHO, an international organization that serves military, political and industrial interests.

The unique nature of HIV has hampered the search for an Aids vaccine and it remains a distant prospect, the world's leading experts say.

When American politicians announced the discovery of HIV in 1984, they predicted that a vaccine and a cure for Aids would be available within five years. It turned out to be a hopelessly optimistic assessment as the immense technical and scientific difficulties unfolded.

Nevertheless, the discovery of the virus led to important developments. The first was a blood test to determine whether someone was HIV positive. A global research effort into the genetics and biology of HIV led to a deeper understanding of the virus's modus operandi. This pointed to ways of sabotaging viral replication in infected patients.

An Australian company is in a global race to produce a vaccine for diseases such as HIV and cancer.

The privately-owned company Replikun Biotech Pty Ltd has used the kunjin virus, found in mosquitoes from the wet tropics region of north Queensland, to make an injectable vaccine after processing with gene technology.

Replikun Biotech says laboratory testing has yielded promising results and the company has now reached the stage where the vaccine could be tested on monkeys, and if that is successful, on humans.

Replikun Biotech chief executive Shane Storey said the class of vaccines under development activated parts of the immune system which conventional vaccines could not kick-start.

MALVERN, Pa. — Drug developer Novavax Inc. on Tuesday said the Centers for Disease Control and Prevention agreed to test the company's bird flu vaccine against a live strain of the H5N1 virus that causes the disease.

Under the agreement, Novavax will provide the CDC with a year's supply of its virus-like particle, or VLP, H5N1 vaccine. Novavax also plans to begin human testing of the vaccine in the first half of 2007.

VLPs are structures that are identical to a virus but lack the genetic material required to replicate, allowing for the body to produce an immune response without risking an infection.

Novavax shares rose 47 cents, or 11.5 percent, to $4.57 in premarket electronic trading, after closing at $4.10 Monday on the Nasdaq.

source 

Scientists are working on a vaccine against drug-resistant staph bacteria such as MRSA.

MRSA is methicillin-resistant Staphylococcus aureus. It resists treatment with many antibiotics.

MRSA infections are rising worldwide. It often infects the skin but can also infect the blood, lungs, urinary tract, and other parts of the body.

University of Chicago scientists are targeting staph bacteria -- including MRSA -- with an experimental vaccine.

Even as Mid-South health providers gear up to begin vaccinating against one sexually transmitted disease, the human papillomavirus (HPV), Memphis researchers are working on vaccines against two more.

At St. Jude Children's Research Hospital, Drs. Karen Slobod and Julia Hurwitz have been working for more than a decade on a vaccine to protect against the AIDS virus. Although medications have helped transform AIDS from a rapidly fatal to a chronic disease, there is still no vaccine or cure.

Human testing with the experimental vaccine began in the late 1990s. In a statement, Dr. Elaine Tuomanen, chairwoman of St. Jude's department of infectious disease, said a final round of safety testing is expected to begin early next year. She indicated the next step will be determined by those results along with the immune response the vaccine sparks.

An anthrax vaccine developed by three KU researchers is in its second stage of clinical testing.

The vaccine is a stabilized liquid form of the current anthrax vaccine, which is difficult to transport and store because its temperature must remain constant. Duane Brandau, Sangeeta Joshi and Laura Peek, KU research professors, developed a stabilized liquid form of the vaccine and sent it to a laboratory that converted their vaccine to a powder form. Then the vaccine went to its first of up to four stages of clinical testing. The powder vaccine doesn’t have such specific conditons for storage, making it easier to transport. It is administered through an inhaler or a nasal spray. The current vaccine is a liquid and administered by injection.

Research into a vaccine for Alzheimer's disease, which was stopped early on safety grounds, is to be resurrected.

It was designed to reverse the disease's progression by clearing the beta amyloid protein that causes the disease.

But the trial was halted in 2002 when 6% of patients in the second phase of the study developed brain inflammation.

Maputo - The first vaccine against malaria could be on the market by 2010 following trials in Mozambique, the southern African country's deputy health minister told an international conference on Tuesday.

"We think the first malaria vaccine will be available by 2010 if the tests in Manhica (north of the capital Maputo) are effective," Aida Libombo told the gathering of health professionals.

LONDON (AFX) - Bavarian Nordic AS said it has started a Phase I and a Phase I/II clinical study in Europe with MVA-BN polytope vaccine against HIV.

The vaccine was recently released from the company's facility in Berlin for use in clinical trials.

Results from both studies are expected in the second half of 2007.

MVA-BN polytope is the second of the company's three vaccine candidates to enter clinical trials.

source

It seems that researchers are running out of deadly and not so deadly diseases.

"Dr. Jeffrey Taubenberger, a government researcher who used molecular techniques to reconstruct all eight genes of the Spanish flu virus, has suggested that even with today's medical advances, an equally virulent flu strain could kill 100 million people or more worldwide."

We can only hope that this reconsturcted virus won't get released by accident... or can't we?

I let you read the whole article below..

Newswise — A team of University of Iowa Health Care researchers has launched an important clinical trial of a novel therapeutic that may eventually lead to new treatments for men diagnosed with prostate cancer.

The Ad5-TRAIL gene therapy for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.

The clinical study is being co-led by Thomas Griffith, Ph.D., an associate professor in the UI Department of Urology, and Richard Williams, M.D., the Rubin H. Flocks Chair in Urology and professor and head of the UI Department of Urology.

LONDON (AFX) - Cobra Bio-Manufacturing PLC said it has signed a research and development agreement with the Naval Medical Research Center of the US Navy to construct and test a vaccine against malaria.

The venture will use Cobra's proprietary ORT-VAC oral vaccine delivery technology.

NEW DELHI: Sensing an opportunity in the dengue outbreak, major pharma companies — including GlaxoSmithKline (GSK), Novartis and Sanofi Pasteur — are developing a treatment and preventive against the disease.

While leading vaccine manufacturers, GSK Biologicals and Sanofi Pasteur are working on a vaccine which will be a preventive against the disease, Novartis is developing a drug for its treatment.

WASHINGTON: Montana State University Virologist Bill Halford has successfully tested a herpes vaccine in mice, opening new avenues for the development of a new vaccine to prevent humans from contacting genital herpes and other diseases caused by herpes simplex viruses.

In a study published earlier this year in the Virology Journal, MSU Virologist William Halford had shown that mice exposed to genetically modified herpes simplex virus type 1 (HSV-1) did not show any sign of disease 30 days after being exposed to a particularly lethal ‘wild-type’ strain of the virus.

Scientists at Makerere University, in Uganda, along with scientists from Johns Hopkins and other institutions worldwide, have begun the first clinical safety trial in Africa of a vaccine to prevent mother-to-child transmission of HIV through breastfeeding, according to a news release from Johns Hopkins Friday.

Breast milk is a leading route of infection in the developing world, according to the World Health Organization, which estimates that each day 1,800 newborns are infected with the AIDS virus, 30 percent to 40 percent by virus carried in their mother's milk.

By Tan Ee Lyn, Reuters, 12 Oct 2006

BEIJING, Oct 12 (Reuters) - A Chinese company that is developing a H5N1 bird flu vaccine for humans plans to kick off a second clinical trial before the end of the year and will have its production capacity expanded ten-fold by mid-2007.

"The second clinical trial should be over by July or August next year, just before the flu season begins," Yin Weidong, managing director of state-backed Beijing Sinovac Biotech Co., told Reuters in an interview on Thursday.

He tried to ease concerns over using a strain of the virus found in Vietnam in the vaccine, saying it would offer some protection against other H5N1 strains.

ATLANTA, Oct. 11 (UPI) -- Several new vaccines have been licensed and approved for use within the past year -- extending the immunization period from childhood into adolescence.

Dr. Larry Pickering of the Centers for Disease Control and Prevention in Atlanta and Dr. Carol Baker of Baylor College of Medicine in Houston gave an update on new vaccines currently available at the American Academy of Pediatrics National Conference and Exhibition in Atlanta.